Company ProfilePremium

I G Petrochemicals Limited

Company Profile Analysis

Ticker: IGPL.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
I G Petrochemicals Limited - Company showcase

Year Founded & Workforce

1988

82 Employees

I G Petrochemicals Limited logo

I G Petrochemicals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

I G Petrochemicals Limited Overview

I G Petrochemicals is India's largest producer of phthalic anhydride (PAN), the building block for phthalate plasticisers, alkyd and unsaturated polyester resins, and pigments. Commonly cited estimates put its share of the domestic market at about 50%. All production sits in one integrated complex at Taloja, near Mumbai's ports. The complex has five PAN plants with 2,22,110 MTPA of installed capacity, which places IGPL among the largest single-site PAN producers globally. It also has four small maleic anhydride (MAN) units that recover MAN from PAN process wash water; IGPL describes itself as India's only MAN producer. Benzoic acid and diethyl phthalate (DEP) complete the derivative range. The business is a commodity spread business: earnings track the gap between PAN prices and the cost of its ortho-xylene (OX) feedstock, and that gap is shaped by Chinese and Korean import competition and India's anti-dumping duties. Management is now moving downstream into plasticisers (a 75,000 TPA plant) and into compressed biogas, aiming to make earnings less cyclical.


What the company does

IGPL converts ortho-xylene, a refinery-derived aromatic, into phthalic anhydride by catalytic vapour-phase oxidation. Its original process technology came from Lurgi of Germany, which was a technical and financial collaborator when the project was promoted. The plant was conceived as a 100% Export-Oriented Unit (EOU) with a licensed capacity of 45,000 tpa. At the time, that made it the largest PAN plant in India and larger than the typical 35,000 tpa international plant.

Over three decades the site has been expanded in phases (PA-1 to PA-5) to 2,22,110 MTPA. The Company also earns revenue from:

Maleic anhydride (MAN): recovered from wash water generated in PAN production, so it is effectively a by-product monetisation stream. Capacity is 7,660 MTPA across four units.

Benzoic acid: a further by-product and derivative stream.

Diethyl phthalate (DEP): a PAN derivative used in personal care products, incense sticks, cosmetics and toiletries. A debottlenecking programme is under way.

Plasticisers (new): a 75,000 TPA greenfield plant at Taloja producing DOP, DINP and DIPP. It reached mechanical completion in March 2026, and management expects commercial production in September–October 2026.

Compressed biogas (new): a CBG plant run through IG Biofuels Limited, processing organic waste. Mechanical completion is targeted for Q2 FY2027 and operations for Q3 FY2027.

Business and revenue model

The revenue model is entirely product sales: bulk industrial chemicals sold by the tonne to manufacturers. There is no service, subscription or licensing revenue. Pricing is set by the market and moves with international PAN benchmarks (Asian CFR prices) and OX feedstock costs, so profitability depends on the PAN–OX spread rather than on list pricing.

Non-PAN revenue (MAN, benzoic acid, DEP and others) is still small. Management disclosed non-PAN revenue of ₹49 cr in Q1 FY2027, about 8% of quarterly revenue.

Value-chain position

IGPL is a mid-stream intermediate producer:

Upstream: refiners and aromatics producers supply ortho-xylene. Indian refiners are a source, and imports are available because Taloja is close to the JNPT and Mumbai ports.

IGPL: converts OX into PAN and recovers MAN, benzoic acid and DEP.

Downstream: customers include plasticiser makers (phthalates for flexible PVC), paint and coatings makers (alkyd resins), unsaturated polyester resin (UPR) and fibreglass composite makers, and dye and pigment producers (for example copper phthalocyanine).

End-markets: PVC cables, leather cloth, footwear, flooring, automotive, construction, paints and infrastructure.

The plasticiser project integrates IGPL one step forward. It will consume its own PAN and sell plasticisers directly to PVC compounders, capturing part of the margin that currently goes to its customers.

Customer types and end-markets

Customers are industrial B2B buyers. The main segments are plasticiser manufacturers, paint companies (alkyd resin makers), UPR and composites producers, pigment and dye producers, and makers of agro and food intermediates (for MAN). Domestic sales dominate. Exports were about 10% of revenue in Q1 FY2027, against roughly 20% cited in a broker initiation note several years earlier, so the export share has fallen as domestic demand absorbed added capacity.

The Company's own description vs. independent characterisation

Company framing (investor presentations): IGPL presents itself as India's largest PAN manufacturer and among the top five globally. Its stated vision is to become a well-diversified chemicals company while keeping its leadership position in phthalic anhydride. The FY2026 Directors' Report frames the plasticiser plant as positioning the Company for the growing Indian plasticiser market.

Independent characterisation: IGPL is a scale-advantaged, cyclical, single-site, single-molecule commodity producer. It sits low on the domestic cost curve: proximity to the port lowers logistics costs, the site is large, and by-product recovery adds revenue. Earnings are still dominated by a spread it does not control, as shown by EBITDA moving from ₹407 cr (FY2022) to ₹105 cr (FY2024), back to ₹221 cr (FY2025) and down to about ₹101 cr (FY2026). The current capex cycle (PA-5, plasticisers, DEP, CBG) is the first serious attempt to break that dependence. Its success will decide whether the stock earns a structurally higher multiple.

Strategy

Stated strategy

In its investor presentations and Annual Reports, IGPL describes three strategic themes:

  1. Defend PAN leadership: keep about 50% domestic share, run at high utilisation and stay the low-cost producer through scale (five plants at one site), port proximity and by-product recovery.

  2. Diversify into non-PAN chemistry: grow MAN, benzoic acid and DEP (debottlenecking) to raise the non-PAN revenue share. The vision statement is to become a well-diversified chemicals company while remaining the PAN leader.

  3. Forward integration and green diversification: the 75,000 TPA plasticiser plant and the CBG project.

Initiative register (last 24 months)

InitiativeAnnounced / statusInvestmentTarget / metricStatus (Oct 2026)
PA-5 PAN plantProduction from 12 Feb 2024—Raises PAN capacity to 2,22,110 MTPAOperating
Advance plasticiser plant (DOP, DINP, DIPP), TalojaBoard approval 2024; completion pushed to Mar 2026 (Nov 2025)₹165 cr excluding GST75,000 TPA; 2,000–2,500 t/month initially; FY2027 about 15,000–25,000 t; FY2028 about 50,000–65,000 tMechanically complete Mar 2026; commercial start guided Sep–Oct 2026
DEP debottleneckingFY2026–FY2027—FY2027 DEP volume about 8,000–12,000 tIn progress
CBG plant (IG Biofuels Ltd)Launched FY2025; up to ₹100 cr investment approved Nov 2025About ₹32 cr projectMechanical completion Q2 FY2027; operations Q3 FY2027Under construction
Effluent treatment plant upgrade2024 presentation—Environmental complianceCommissioned (per presentation)
Trade-remedy advocacy (anti-dumping duty)ADD extended from 1 Aug 2026—ADD about US$40/t on China and about US$140/t on Korea (per management)In force for five years

Guidance and medium-term targets

Management does not give EBITDA margin or profit guidance, citing market volatility and geopolitical uncertainty (Q1 FY2027 call coverage). Operational guidance for FY2027:

  • PAN volume about 2,00,000 t (after shutdowns at two plants);

  • Plasticisers about 20,000–25,000 t annualised for FY2027, ramping to 50,000–65,000 t (some coverage says up to 75,000 t) in FY2028;

  • DEP about 8,000–12,000 t;

  • Plasticiser EBITDA margin 10–12%; annual interest and depreciation for the plasticiser plant about ₹10 cr each.

Products & Services

Pricing model: spot and contract prices linked to market; no list pricing is disclosed. Management estimates the plasticiser business typically earns 10–12% EBITDA margins, with net margins averaging about 4–5% over the last four to five years (Q1 FY2027 concall).

Brands: IGPL sells under its corporate name; no consumer brands.

Product Portfolio

ProductDescription and chemistryKey applications / target customersCapacity and statusNotes

Phthalic anhydride (PAN)

C8H4O3; made by catalytic oxidation of ortho-xylene; sold as flakes or molten

Phthalate plasticisers (DOP/DEHP, DINP, DIDP) for flexible PVC; alkyd resins (paints); unsaturated polyester resins; copper phthalocyanine pigments; dyes

2,22,110 MTPA across five plants (PA-1 to PA-5); PA-5 started 12 Feb 2024; FY2027 volume guidance about 2,00,000 t, allowing for shutdowns at two plants

Core product; domestic share about 50%; protected by anti-dumping duty extended from 1 Aug 2026

Maleic anhydride (MAN)

C4H2O3; recovered from PAN wash water

UPR, alkyd resins, agro and food intermediates, lubricant additives

7,660 MTPA across four units

IGPL says it is India's only MAN producer; Indian MAN demand was about 55,000 MTPA (older company presentation), so India relies heavily on imports

Benzoic acid (BA)

Aromatic carboxylic acid; by-product / derivative stream

Preservatives, plasticisers, alkyd resins, intermediates

—

Part of non-PAN revenue

Diethyl phthalate (DEP)

Ester of PAN and ethanol

Personal care, cosmetics, incense sticks, toiletries, fragrance fixative

Debottlenecking under way; FY2027 volume guidance about 8,000–12,000 t

Higher-value PAN derivative

Plasticisers — DOP / DEHP

Dioctyl phthalate; general-purpose PVC plasticiser

PVC compounders: cables, flooring, leather cloth, footwear

Part of 75,000 TPA plant; mechanical completion Mar 2026

Commercial start guided for Sep–Oct 2026

Plasticisers — DINP

Diisononyl phthalate; higher-molecular-weight, lower-volatility plasticiser

Automotive, wire and cable, flooring

Part of 75,000 TPA plant

Faces some regulatory scrutiny in export markets

Plasticisers — DIPP

Phthalate-family plasticiser (exact grade as named by management)

PVC compounding

Part of 75,000 TPA plant

Product specification not detailed in sources reviewed

Compressed biogas (CBG)

Methane-rich biogas from organic waste

Gas marketing companies (likely under India's SATAT scheme; offtake partner not confirmed), industrial users

About ₹32 cr project; mechanical completion targeted Q2 FY2027; operations Q3 FY2027

Run through IG Biofuels Limited

"Advance plasticisers"

Referred to in some database profiles as an 8,400 MTPA "Advance Plasticizers" capacity

Not specified

Status unclear

Discrepancy: the Company calls the new 75,000 TPA project the "Advance Plasticizer plant"; the 8,400 MTPA figure may be an older or smaller product line.

Financial Narrative

Basis: consolidated Ind AS financials, ₹ crore, unless stated. Main sources: Screener.in consolidated history (FY2022–FY2025), Tapetide consolidated series (FY2025–FY2026), company Directors' Reports for FY2025 and FY2026 (standalone), Muthoot Securities standalone P&L, and NSE results filings.

Income statement

Notes and flags:

  • FY2025 and FY2026 depreciation are derived as EBITDA + other income − interest − PBT. FY2026 other income is the standalone figure (total revenue ₹1,953.67 cr less revenue from operations ₹1,924.98 cr). FY2026 interest (≈₹41 cr) comes from MarketScreener/Zonebourse data, not a filing.

  • FY2025 standalone figures from the Company: revenue from operations ₹2,206.23 cr; total revenue ₹2,233.97 cr; PBT ₹144.33 cr; PAT ₹112.47 cr. FY2026 standalone: revenue from operations ₹1,924.98 cr (−12.7%); total revenue ₹1,953.67 cr (−12.5%); PBT ₹31.36 cr; PAT ₹23.16 cr.

  • FY2026 consolidated PAT of about ₹2 cr is the sum of quarterly consolidated net profit (Q1 −13, Q2 −2, Q3 −11, Q4 +28) per Tapetide. Confirm against the audited FY2026 consolidated statements.

  • Dividends: FY2025 (₹10) and FY2026 (₹5) are confirmed from filings. FY2022–FY2024 DPS are derived from Screener's reported payout ratios (12%, 15%, 58%) multiplied by EPS; verify against the annual reports.

  • Diluted EPS equals basic EPS; there are no dilutive instruments in the sources reviewed.

Margin profile

The raw material ratios are calculated from Muthoot standalone data (FY2022: ₹1,233 cr on ₹1,883 cr; FY2023: ₹1,787 cr on ₹2,352 cr; FY2024: ₹1,749 cr on ₹2,099 cr; FY2025: ₹1,713 cr on ₹2,206 cr). Gross margin is not reported as such under Ind AS. Raw material intensity is the best proxy for the PAN–OX spread: the raw material share of revenue rose from 65.5% to 83.3% between FY2022 and FY2024 as the spread collapsed.

Revenue CAGR: FY2021–FY2026 (5 years) about 11.4% (₹1,124 cr to ₹1,925 cr). FY2022–FY2026 (4 years) about 0.6%. Five-year growth is almost entirely the FY2021–FY2022 price and volume upcycle plus PA-4 and PA-5 volumes; the last four years were flat.

Quarterly trajectory (consolidated, ₹ cr)

Source: Tapetide consolidated quarterly series, plus Sahi and ScanX reports of Company filings for Q1 FY2026 and Q1 FY2027 revenue. Q1 FY2027 consolidated revenue was ₹617.8 cr (+31.4% YoY) and consolidated PAT ₹66.44 cr (vs. a ₹12.99 cr loss). Standalone revenue was about ₹620 cr, standalone operating EBITDA ₹113 cr (vs. ₹2.2 cr; margin 18.25% vs. 0.47%), and standalone PAT ₹70.97 cr (vs. an ₹8.21 cr loss). Total income including other income was ₹625.1 cr.

Data-quality flag: one ScanX headline reported Q1 FY2027 consolidated EBITDA as "₹1,188 crore". That is inconsistent with revenue of ₹618 cr and is almost certainly a units error (about ₹118.8 cr). We have disregarded it.

Balance sheet (consolidated)

FY2025 net worth is derived from the reported book value of ₹431.06 per share × 3.0795 cr shares. The split of borrowings into short- and long-term, cash and equivalents, and net debt for FY2025–FY2026 were not available in the sources reviewed; see the audited balance sheets in the FY2025 and FY2026 Annual Reports. Goodwill appears negligible, since the business was built organically. Borrowings more than doubled from ₹173 cr (FY2022) to ₹368 cr (FY2024) to fund PA-5 and early plasticiser capex, and interest cost tripled from ₹13 cr to about ₹41 cr (FY2026). That indicates further borrowing growth after FY2024; FY2026 interest of about ₹41 cr implies gross debt in the region of ₹450–550 cr at 8–9% cost (analyst inference).

Cash flow (consolidated)

Investing cash flow is used as a capex proxy because it includes treasury investment movements; pure capex is not separated in the sources reviewed. FY2025 dividends paid (about ₹31 cr) is the cash payout of the FY2024-declared dividend, which could not be confirmed. The ₹30.8 cr figure is the FY2025 dividend (₹10/share) paid in FY2026. There have been no buybacks in the sources reviewed.

Interpretation: IGPL produced strong internal cash in upcycle years, but FY2022 OCF (₹109 cr) was well below EBITDA because working capital expanded (CCC 25 days, debtor days 67) during rising prices. FY2024 OCF of only ₹37 cr, combined with PA-5 capex, explains the jump in debt. Cumulative free cash flow over FY2022–FY2024 was negative.

Ratios

ROE and ROA are derived on average and closing balances respectively; FY2025 ROE matches Screener's 8.53%. ROCE comes from Screener (FY2021: 30%). CCC for FY2025–FY2026 comes from Tapetide. ROIC is not reported; ROCE serves as a proxy. The current ratio was not disclosed in the sources reviewed. Net debt/EBITDA cannot be computed reliably for FY2025–FY2026 without balance-sheet data; on FY2024 gross debt of ₹368 cr and EBITDA of ₹105 cr, gross debt/EBITDA was about 3.5x, a cyclical high.

Trend commentary

  1. FY2022 peak: PA-4 volumes (commissioned December 2020) coincided with a global PAN spread spike, producing EBITDA of ₹407 cr at a 21.6% margin and ROCE of 35%.

  2. FY2023 normalisation: revenue grew 25% on price, but margins halved as OX costs rose faster than PAN prices.

  3. FY2024 trough: Chinese capacity additions and weak export pricing compressed spreads. EBITDA margin fell to 5%, and Q3 FY2024 showed a negative operating profit of −₹6 cr. PA-5 was commissioned into a weak market.

  4. FY2025 partial recovery: EBITDA +82% to ₹248 cr (standalone including other income) and PAT +183%, helped by PA-5 volumes and better spreads.

  5. FY2026 second trough: revenue −12.7%, standalone PAT −79%. The decline came from plant shutdowns (management cited two-plant shutdowns and "plant shutdown impacts" in Q1 FY2026), weak paints demand (a prolonged monsoon also hurt peer Thirumalai), and narrow spreads. Three of four quarters were loss-making on a consolidated basis.

  6. Q1 FY2027 inflection: an 18.25% standalone EBITDA margin was the strongest since FY2022. Management attributes it mainly to improved realisations and normalised operations. Sustainability depends on the PAN–OX spread and the renewed anti-dumping duty.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (INR Cr)FY2024FY2025FY2026

Total revenue from operations, consolidated

2,0992,2061,925

Group Entities

EntityRelationshipActivity

I G Petrochemicals Limited

Parent, listed

PAN, MAN, benzoic acid, DEP; plasticisers (from FY2027)

IGPL International Limited

Subsidiary

International / trading activities (scope not detailed in sources reviewed)

IGPL Energy Limited

Subsidiary

Energy-related activities (scope not detailed)

IG Biofuels Limited

Subsidiary

Compressed biogas project; board approved investment of up to ₹100 cr (Nov 2025)

IGPL Charitable Foundation

Subsidiary

CSR delivery

IGPL (FZE)

Historical wholly owned subsidiary (UAE)

—

Mysore Petro Chemicals Ltd

Promoter group company

Trading of OX, PAN, MAN, benzoic acid; former PAN/MAN producer

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr, consolidated)

1,8832,3522,0992,2061,925

Revenue growth YoY (%)

67.524.9-10.85.1-12.7

Other income (INR Cr)

622302829

EBITDA excluding other income (INR Cr, consolidated)

407318105221101

Interest (INR Cr)

1324303941

Depreciation (INR Cr)

4447526679

Profit before tax (INR Cr, consolidated)

3562685314410

Effective tax rate (%)

2625262379

Net profit (INR Cr, consolidated)

264200401092

Net profit (INR Cr, standalone)

2642004011223

EPS basic (₹, consolidated)

85.8964.9512.8335.40.6

EPS basic (₹, standalone)

85.964.9512.8336.57.52

Dividend per share (INR)

10107.5105

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

21.613.55.010.05.2

PBT margin (%)

18.911.42.56.50.5

Net margin (%, consolidated)

14.08.51.94.90.1

Raw material cost / revenue (%, standalone)

65.576.083.377.7—

Financial Analysis

MetricQ1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations

————470———618

Operating profit (EBITDA ex other income)

62634747-120867112

Profit before tax

45343625-16-1-134090

Net profit

35262919-13-2-112866

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

3131313131

Reserves (INR Cr)

1,0311,2041,216——

Net worth (INR Cr)

1,0621,2351,2471,327—

Book value per share (INR)

345401405431—

Total borrowings (INR Cr)

173254368——

Other liabilities (INR Cr)

416503520——

Total assets (INR Cr)

1,6511,9922,135——

Net fixed assets (INR Cr)

7367171,030——

Capital work-in-progress (INR Cr)

118349158——

Investments (INR Cr)

81182144——

Other assets incl. working capital and cash (INR Cr)

716745803——

Goodwill and intangibles (INR Cr)

000——

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (INR Cr)

18310923337—

Investing cash flow (INR Cr)

-72-106-255-115—

Financing cash flow (INR Cr)

-80-192148—

Net cash flow (INR Cr)

30-15-2-29—

Free cash flow, OCF + investing proxy (INR Cr)

1113-22-78—

Dividends paid (INR Cr)

————31

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

28.017.43.28.50.2

ROCE (%)

3522511—

ROA (%)

16.010.01.9——

Debt / equity (x)

0.160.210.30——

EBITDA / interest (x)

31.313.33.55.72.5

Asset turnover (x)

1.141.180.98——

Debtor days

675059——

Inventory days

453442——

Payable days

877679——

Cash conversion cycle (days)

258211323

Dividend payout (%)

12155828—

Share Price History

DatePrice (INR)Source

27 Mar 2025

429.75

Trendlyne

10 Apr 2026

424.00

ICICI Direct

13 Apr 2026

413.20

Kotak Neo

10 Jul 2026

432.15

IIFL

20 Aug 2026

471.05

InCred Money

30 Sep 2026

587.70

MarketScreener / Zonebourse (+47.83% year to date; +0.58% on the day)

Valuation Multiples

MultipleIGPLBasis

Market cap (INR Cr)

1,810

₹587.70 × 3.0795 cr shares

P/E, trailing (x)

22.3

TTM consolidated PAT about ₹81 cr (Q2 FY2026 to Q1 FY2027)

P/B (x)

1.4

BVPS about ₹422–431

Market cap / TTM EBITDA (x)

8.7

TTM EBITDA ₹207 cr

Dividend yield (%)

0.9

₹5 FY2026 DPS / ₹587.70

Income Statement

Metric (INR Cr)FY2024FY2025FY2026FY2027EFY2028E

Revenue

2,0992,2061,9252,4562,935

EBITDA

10521995285252

Interest paid

3039413731

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

10107.5105

Credit Ratings

AgencyInstrumentRatingOutlookDate

India Ratings & Research (Fitch group)

Long-term bank facilities / term loans

IND AA-

Stable

Affirmed and assigned 14 Oct 2025

India Ratings & Research

Short-term / non-fund-based

IND A1+

—

Affirmed 14 Oct 2025

Moody's / S&P / Fitch (global)

—

Not rated

——

Analyst Conclusions

Management guidance (FY2027)

PAN volume is guided at about 2,00,000 t; plasticisers at about 15,000–25,000 t in FY2027 rising to 50,000–65,000 t in FY2028, at 10–12% EBITDA margins; DEP at 8,000–12,000 t; and CBG operations starting in Q3 FY2027. There is no margin or profit guidance.

Consensus

FY2027E revenue is about ₹2,456 cr and EBITDA about ₹285 cr. For FY2028E, revenue is about ₹2,935 cr and EBITDA about ₹252 cr.

Bull case

  1. Cyclical upturn plus protection: Q1 FY2027's 18.25% standalone EBITDA margin, on a capacity base 27% larger than the FY2022 peak (PA-5), plus five years of anti-dumping cover. Sustained mid-teens margins would imply annual EBITDA above ₹350 cr.

  2. Structural mix shift: a 75,000 TPA plasticiser plant at 10–12% margins adds a less volatile earnings stream that uses IGPL's own PAN.

  3. Survivor advantage: Thirumalai's FY2026 consolidated loss of ₹202 cr and negative EBITDA leave IGPL as the financially strongest Indian PAN producer, which supports pricing discipline and share gains.

Bear case

  1. Spread mean-reversion: in each of the past four years, one strong period was followed by a collapse. Chinese supply and OX volatility can quickly erase Q1 FY2027's gains, and the US$40/t duty on China is small.

  2. Execution and dilution risk: the plasticiser plant is already about two quarters late. Plasticiser margins (10–12%) are below PAN's peak margins, and consensus shows FY2028 EBITDA falling despite higher revenue.

  3. Concentration and balance-sheet risk: single-site operations (FY2026 shutdowns), rising debt and interest (coverage 2.5x in FY2026), and negative free cash flow in capex years.

Catalysts and monitorables (next 12 months)

  • Q2 FY2027 results (expected November 2026): whether spreads held after Q1.

  • Formal announcement of plasticiser commercial production and monthly run rates (target 2,000–2,500 t/month).

  • CBG commissioning in Q3 FY2027.

  • PAN–OX spread and Chinese export pricing.

  • Re-issue of the India Ratings rating (around Oct 2026).

  • Net debt and capex disclosures in the H1 FY2027 balance sheet.

  • Any segment reporting change.

  • Promoter holding and dividend policy.

Analyst verdict

I G Petrochemicals is a high-quality operator in a low-quality, cyclical product. Its competitive position has strengthened over the past three years. It holds about half of India's PAN market, operates the country's largest and lowest-cost capacity, carries an AA- rating, and stayed profitable through a down-cycle that pushed its nearest domestic rival into heavy losses. The renewal of anti-dumping duties to 2031 and the addition of PA-5 capacity give it more leverage to any recovery than at any time in its history. Q1 FY2027 showed that leverage: a standalone EBITDA margin of 18.25% on revenue up 31%.

The investment question, however, is not whether IGPL is the best PAN producer; it plainly is. The question is whether management can make earnings less cyclical. The record is mixed. Diversification has been slow, the non-PAN share is still under a tenth of revenue, and the plasticiser plant is roughly two quarters behind schedule. The plasticiser business also moves IGPL further into ortho-phthalates, which face growing regulatory scrutiny, and at lower margins than PAN at mid-cycle. Debt and interest have also risen steadily through the capex phase.

At about ₹588 per share (around 22x trailing earnings, about 1.4x book and about 9x trailing EBITDA before debt), the market has partly priced in recovery: the stock is up about 48% this year. The risk-reward now depends on whether spreads persist and plasticisers ramp up on schedule. If both hold, FY2027–FY2028 earnings could approach FY2023 levels, and the current valuation would look undemanding against a cash-generative, dividend-paying market leader. If spreads revert, as they have in each recent cycle, the shares trade back toward book value.

On balance, IGPL is a well-managed cyclical with an improving but not yet proven diversification story. It is best owned by investors who can monitor spreads closely, and who treat confirmation of plasticiser commercial production and Q2–Q3 FY2027 margins as the decisive checkpoints.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / background (as disclosed)

M M Dhanuka

Chairman (Promoter, Non-Executive / Executive status to verify)

Long-time promoter; listed as MD of Mysore Petro Chemicals; background in chemicals sales, marketing and commercial roles

Nikunj Dhanuka

Managing Director & CEO (Promoter)

Leads strategy and diversification; MD & CEO per 2021 investor presentation and current profiles

Pramod Bhandari

Chief Financial Officer

Led the Q1 FY2027 earnings call (7 Aug 2026)

Sudhir R Singh

Company Secretary & Compliance Officer

Signs exchange filings (2019–2025)

Sanjoy Datta

Director (role to verify)

Appointed at Nov 2025 board meeting

Executive Director

—

Responsible for Taloja plant per 2021 presentation

Major Shareholders

Holder category% holding (Dec 2025)

Promoter and promoter group (Indian)

68.74

Foreign promoter

0.00

Public (all non-promoters)

31.26

Of which: institutions (FII, DII, MF), indicative

about 4.5

Competitive Landscape

Key Competitors

CompetitorCountrySegment overlapRelative positioning

Thirumalai Chemicals Ltd (TCL)

India

PAN, MAN, fumaric and malic acid

#2 domestic PAN producer; diversified into food acids (including a US facility); FY2026 revenue ₹1,735 cr; consolidated loss of about ₹202 cr

Asian Paints Ltd (captive PAN)

India

PAN (captive for alkyd resins)

Captive consumer and producer; reduces merchant demand

Mysore Petro Chemicals Ltd

India

PAN / MAN trading

Promoter-group affiliate; trading only

Aditya Chemicals (historical)

India

PAN

—

BASF SE

Germany

PAN, plasticisers

Historically the world's largest PAN producer (about 400,000 tpa at ten sites per 2007 reports); global price-setter

Nan Ya Plastics Corp.

Taiwan

PAN, plasticisers

Large integrated Asian producer and exporter

Chinese PAN producers (several)

China

PAN

Main source of import pressure; covered by Indian anti-dumping duty

Korean PAN producers (e.g., Aekyung Chemical)

South Korea

PAN, plasticisers

Exporters to India; subject to anti-dumping duty (about US$140/t per IGPL management)

Polynt Group

Italy

PAN, MAN, resins

European integrated anhydrides and resins player

Stepan Company

USA

PAN (polyols), surfactants

Western PAN producer, largely captive

ExxonMobil Chemical

USA

DINP plasticisers

Global plasticiser leader; competitor for IGPL's new DINP output

KLJ Group

India

Plasticisers (DOP, DINP, others)

Leading domestic plasticiser producer; main competitor in the new segment

UPC Technology Corp.

Taiwan

PAN, plasticisers

Asian integrated PAN-to-plasticiser producer

Peer Comparison FY2026

MetricIGPLThirumalai Chemicals

FY2026 revenue (INR Cr, consolidated)

1,9251,735

FY2026 revenue growth (%)

-12.7-15.3

FY2026 EBITDA (INR Cr)

101-23

FY2026 EBITDA margin (%)

5.2-1.3

FY2026 net profit (INR Cr, consolidated)

2-202

FY2025 EBITDA margin (%)

10.02.3

Market cap (INR Cr)

about 1810 (30 Sep 2026)

about 2099 (mid-2026)

PAN capacity (MTPA)

222,110—

Company Snapshot

$222.3M

Revenue

82

Employees

1988

Founded

Panaji, India

Headquarters

SWOT Analysis

Strengths

  • Domestic market leadership: about 50% Indian PAN share (IIFL; Company), from the largest PAN capacity in India (2,22,110 MTPA).
  • Cost leadership shown in the down-cycle: FY2026 EBITDA of ₹101 cr and positive PAT while Thirumalai posted negative EBITDA (−₹23 cr) and a ₹202 cr consolidated loss.
  • Strong investment-grade credit: IND AA-/Stable and IND A1+ affirmed October 2025, up from IND A+ in 2019.
  • Operating leverage: a revenue rise of about 31% YoY in Q1 FY2027 lifted standalone EBITDA from ₹2.2 cr to ₹113 cr.
  • Consistent dividends through the cycle: ₹10 (FY2025) and ₹5 (FY2026) even in a near-zero consolidated profit year.
  • By-product integration: sole Indian MAN producer, using PAN wash water.

Weaknesses

  • Single-product concentration: non-PAN revenue was only ₹49 cr of ₹618 cr in Q1 FY2027 (about 8%).
  • Severe earnings volatility: consolidated PAT went ₹264 cr (FY2022) → ₹40 cr (FY2024) → ₹109 cr (FY2025) → about ₹2 cr (FY2026).
  • Weak cash conversion in peak years: FY2022 OCF of ₹109 cr against EBITDA of ₹407 cr.
  • Rising leverage and interest burden: borrowings ₹173 cr (FY2022) to ₹368 cr (FY2024); interest ₹13 cr to about ₹41 cr (FY2026).
  • Project slippage: plasticiser commissioning moved from Q3 FY2026 (FY2025 Annual Report) to a September–October 2026 commercial start.
  • Single-site risk: two-plant shutdowns hit FY2026 volumes and Q1 FY2026 margins (0.47% standalone EBITDA margin).

Opportunities

  • Plasticiser ramp-up: 75,000 TPA at the guided 10–12% EBITDA margin. At about 60,000 t and an assumed realisation of about ₹1–1.2 lakh/t, that could add roughly ₹600–700 cr of revenue (analyst illustration, not guidance).
  • Anti-dumping duty extension: five years from 1 Aug 2026 on Chinese and Korean PAN.
  • Competitor weakness: Thirumalai's losses and stretched balance sheet (contingent liabilities ₹1,234 cr per Screener) may limit new domestic PAN capacity.
  • DEP debottlenecking: 8,000–12,000 t FY2027 volume in a higher-value derivative.
  • CBG and green energy: policy-supported revenue stream; diversification benefit for ESG ratings.
  • Infrastructure-led demand: management cited supportive infrastructure and manufacturing demand on the Q1 FY2027 call.

Threats

  • Chinese oversupply: caused the FY2024 and FY2026 troughs; the anti-dumping duty at about US$40/t on China is modest relative to spread swings.
  • OX feedstock volatility: raw material share of revenue swung from 65.5% to 83.3% within two years (FY2022–FY2024).
  • Regulatory pressure on phthalates: EU restrictions on DEHP-type plasticisers could cap export potential for the new DOP output.
  • Paint-demand seasonality: a prolonged monsoon hurt paints-linked PAN demand in FY2026 (Thirumalai Q3 FY2026 commentary).
  • Execution risk on two new businesses at once (plasticisers and CBG), with about ₹10 cr each of annual interest and depreciation added for plasticisers.
  • Concentration of governance in the promoter family: 68.74% promoter holding and a promoter Chairman and CEO.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
19 May 2025FY2025 audited results; ₹10/share dividend recommended (about ₹30.8 cr)Profit recovery: standalone PAT about ₹112 cr (+183%)
May 2025FY2025 investor presentation and earnings callPlasticiser plant targeted for Q3 FY2026 commissioning
14 Jul 2025FY2025 Annual Report: revenue ₹2,234 cr, EBITDA ₹248 cr (+82%), PAT ₹112 crConfirms recovery; CBG and plasticisers set out as diversification pillars
1 Aug 2025Charge creation recorded (MCA)Likely project debt for plasticisers (to verify)
7 Aug 202536th AGMApproves FY2025 accounts and dividend
Aug 2025Q1 FY2026 results: consolidated loss of ₹13 cr; standalone EBITDA ₹2.2 cr (0.47% margin)Trough quarter; plant shutdown impact
14–15 Oct 2025India Ratings assigns and affirms IND AA-/Stable/IND A1+ on bank facilitiesCredit standing intact despite earnings slump
27 Oct 2025Board meeting called for 3 Nov 2025; trading window closedRoutine
3 Nov 2025Q2 FY2026 results (consolidated loss of about ₹2 cr); Sanjoy Datta appointed; plasticiser timeline extended to Mar 2026; up to ₹100 cr investment in IG Biofuels approvedProject delay of about one quarter; CBG funding committed
10 Dec 2025General update filed with NSEContent not captured
11 Dec 2025Investor meeting schedule filedInvestor outreach
16 Jan 2026Q3 shareholding: promoters 68.74%, public 31.26%Stable ownership
9 Feb 2026Investor meeting schedule filedOutreach
11 Feb 2026Q3 FY2026 results: consolidated loss of about ₹11 crThird weak quarter
13 Feb 2026Q3 FY2026 investor presentation and earnings call recordingGuidance on plasticiser completion
Mar 2026Plasticiser plant mechanical completionKey milestone met
10–14 Apr 2026Stock about ₹413–424; trailing P/E negative or above 180x, P/B about 1.0xValuation trough
12 May 2026Board meeting intimation for FY2026 resultsRoutine
19 May 2026FY2026 results; final dividend of ₹5/share recommended (about ₹15.4 cr); Q4 FY2026 PAT about ₹28 crRecovery visible in Q4
31 May 2026Analyst coverage of FY2027 volume guidance (PAN about 2,00,000 t; plasticisers; DEP)Sets the FY2027 operating frame
11 Jul 2026AGM noticeRoutine
17 Jul 2026FY2026 Annual Report / Directors' Report publishedCSR obligation ₹299.19 lakh vs. ₹255.14 lakh spent
30 Jul 2026Record date for FY2026 dividend—
31 Jul 2026Board meeting called for 5 Aug 2026Routine
1 Aug 2026Anti-dumping duty on PAN extended for five years (China about US$40/t; Korea about US$140/t per management)Policy support for domestic spreads
5 Aug 2026Q1 FY2027 results: consolidated revenue ₹617.8 cr (+31%); PAT ₹66.4 cr; standalone EBITDA margin 18.25%Strongest quarter since FY2022
6 Aug 202637th AGM: FY2026 accounts, dividend and board appointments approvedGovernance continuity
7 Aug 2026Q1 FY2027 earnings call (CFO Pramod Bhandari)Plasticiser start guided before or around Sep 2026; CBG in Oct–Dec quarter
20 Aug 2026Stock at ₹471.05Post-results re-rating
30 Sep 2026Stock at ₹587.70; +47.8% year to dateStrong momentum into Q2 FY2027
Oct–Nov 2026 (expected)Q2 FY2027 results; plasticiser commercial production announcementNext catalyst; not yet reported

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Total revenue from operations, consolidated fell from INR 20,990 Mn in FY2024 to INR 19,250 Mn in FY2026.
I G Petrochemicals Limited — Revenue by Segment
Series (INR Mn)FY2024FY2025FY2026
Total revenue from operations, consolidated20,99022,06019,250

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. I G Petrochemicals Ltd — Directors' Report FY2025-26 (37th Annual Report), via IIFL / Goodreturns · goodreturns.in
  2. NSE filing — FY2025 audited results (19 May 2025) (nsearchives.nseindia.com)
  3. NSE filing — India Ratings credit rating intimation (15 Oct 2025) (nsearchives.nseindia.com)
  4. BSE filing — Credit rating (30 Sep 2024) (bseindia.com)
  5. BSE filing — Credit rating and office addresses (Sep 2019) (bseindia.com)
  6. BSE filing — Investor presentation (Aug 2021) (bseindia.com)
  7. BSE filing — Investor presentation (2024; PA-5, plasticiser approval, capacities) (bseindia.com)
  8. BSE filing — Earlier investor presentation (MAN market, PA-4) (bseindia.com)
  9. Screener.in — IGPL standalone and consolidated · screener.in
  10. Tapetide — IGPL quarterly and annual series (tapetide.com)
  11. Muthoot Securities — Standalone P&L (muthootsecurities.com)
  12. Torus Digital — IGPL financial summary (torusdigital.com)
  13. FilingReader — FY2025 annual report summary (14 Jul 2025) (filingreader.com)
  14. FilingReader — Credit rating (15 Oct 2025) (filingreader.com)
  15. Multibagg — Q1 FY2027 review (multibagg.ai)
  16. Sahi — Q1 FY2027 standalone and consolidated results; CBG · sahi.com · sahi.com
  17. ScanX — Q1 FY2027 results, AGM, subsidiaries · scanx.trade
  18. GuruFocus — Q1 FY2027 earnings call transcript (7 Aug 2026) (gurufocus.com)
  19. Arthneeti — Q1 FY2027 earnings and concall analysis · arthneeti.com
  20. MarketScreener / Zonebourse — Price and consensus forecasts (ch.zonebourse.com)
  21. Sharekhan — Corporate announcements and shareholding (sharekhan.com)
  22. Infyner — MCA registry profile (infyner.com)
  23. Kotak Securities / Angel One / ICICI Direct / IIFL / InCred / Kotak Neo — Company history and price datapoints · angelone.in · icicidirect.com · indiainfoline.com · incredmoney.com · kotakneo.com
  24. Mysore Petro Chemicals history (Kotak / IIFL) · indiainfoline.com
  25. Plastemart — 2007 PAN expansion and global market context (plastemart.com)
  26. Trendlyne — KR Choksey note excerpt (trendlyne.com)
  27. Thirumalai Chemicals — StockAnalysis, Screener, ScanX, Kotak Neo · screener.in · scanx.trade · thecompanycheck.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.